2026-07-23T23:02:14Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/184972024-11-28T15:43:56Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16958
Repisalud author Sanchez-Varo, Raquel author Sanchez-Mejias, Elisabeth author Fernandez-Valenzuela, Juan Jose author De Castro, Vanessa author Mejias-Ortega, Marina author Gomez-Arboledas, Angela author Jimenez, Sebastian author Sanchez-Mico, Maria Virtudes author Trujillo-Estrada, Laura author Moreno-Gonzalez, Ines author Baglietto-Vargas, David author Vizuete, Marisa author Davila, Jose Carlos author Vitorica, Javier author Gutierrez, Antonia authoraffiliation [Sanchez-Varo,R; Sanchez-Mejias,E; Fernandez-Valenzuela,JJ; De Castro,V; Mejias-Ortega,M; Gomez-Arboledas,A; Trujillo-Estrada,L; Moreno-Gonzalez,I; Baglietto-Vargas,D; Davila,JC; Gutierrez,A] Departamento Biologia Celular, Genetica y Fisiologia, Instituto de Investigacion Biomedica de Malaga-IBIMA, Facultad de Ciencias, Universidad de Málaga, Málaga, Spain. [Sanchez-Varo,R; Sanchez-Mejias,E; Fernandez-Valenzuela,JJ; Mejias-Ortega,M; Gomez-Arboledas,A; Jimenez,S; Sanchez-Mico,MV; Trujillo-Estrada,L; Moreno-Gonzalez,I; Baglietto-Vargas,D; Vizuete,M; Davila,JC; Vitorica,J; Gutierrez,A] Centro de Investigación Biomedica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. [Sanchez-Varo,R] Departamento Fisiologia Humana, Histologia Humana, Anatomia Patologica y Educacion Fisica y Deportiva, Facultad de Medicina, Universidad de Málaga, Málaga, Spain. [Jimenez,S; Sanchez-Mico,MV; Vizuete,M; Vitorica,J] Departamento Bioquimica y Biologia Molecular, Facultad de Farmacia, Universidad de Sevilla, Seville, Spain. [Jimenez,S; Sanchez-Mico,MV; Vizuete,M; Vitorica,J] Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio CSIC/Universidad de Sevilla, Seville, Spain. [Moreno-Gonzalez,I] Department of Neurology, McGovern Medical School, UTHealth Science Center at Houston, Houston, TX, United States 2024-02-19T15:31:55Z 2024-02-19T15:31:55Z 2021-11-04 10.3389/fnins.2021.752594 1662-453X Frontiers in Neuroscience http://hdl.handle.net/10668/4098 34803589 http://hdl.handle.net/20.500.12105/18497 Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by initial memory impairments that progress to dementia. In this sense, synaptic dysfunction and loss have been established as the pathological features that best correlate with the typical early cognitive decline in this disease. At the histopathological level, post mortem AD brains typically exhibit intraneuronal neurofibrillary tangles (NFTs) along with the accumulation of amyloid-beta (Abeta) peptides in the form of extracellular deposits. Specifically, the oligomeric soluble forms of Abeta are considered the most synaptotoxic species. In addition, neuritic plaques are Abeta deposits surrounded by activated microglia and astroglia cells together with abnormal swellings of neuronal processes named dystrophic neurites. These periplaque aberrant neurites are mostly presynaptic elements and represent the first pathological indicator of synaptic dysfunction. In terms of losing synaptic proteins, the hippocampus is one of the brain regions most affected in AD patients. In this work, we report an early decline in spatial memory, along with hippocampal synaptic changes, in an amyloidogenic APP/PS1 transgenic model. Quantitative electron microscopy revealed a spatial synaptotoxic pattern around neuritic plaques with significant loss of periplaque synaptic terminals, showing rising synapse loss close to the border, especially in larger plaques. Moreover, dystrophic presynapses were filled with autophagic vesicles in detriment of the presynaptic vesicular density, probably interfering with synaptic function at very early synaptopathological disease stages. Electron immunogold labeling showed that the periphery of amyloid plaques, and the associated dystrophic neurites, was enriched in Abeta oligomers supporting an extracellular location of the synaptotoxins. Finally, the incubation of primary neurons with soluble fractions derived from 6-month-old APP/PS1 hippocampus induced significant loss of synaptic proteins, but not neuronal death. Indeed, this preclinical transgenic model could serve to investigate therapies targeted at initial stages of synaptic dysfunction relevant to the prodromal and early AD. eng Alzheimer’s disease Synaptic pathology Hippocampus Transgenic mice (Tg) Amyloid Oligomers Enfermedad de Alzheimer Hipocampo Ratones transgénicos Amiloide Morfolinos Plaque-Associated Oligomeric Amyloid-Beta Drives Early Synaptotoxicity in APP/PS1 Mice Hippocampus: Ultrastructural Pathology Analysis research article